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CXCR7 expression disrupts endothelial
cell homeostasis and causes
ligand-dependent invasion
Jennifer E Totonchy1, Lisa Clepper1, Kevin G Phillips2, Owen JT McCarty2, and Ashlee V Moses1,*
Vaccine and Gene Therapy Institute; Oregon Health and Science University; Beaverton, OR USA; 2Department of Biomedical Engineering; Oregon Health and Science
University; Portland, OR USA

Keywords: PECAM-1, CXCR7, endothelial cell adhesion, invasion, cancer vascular dysfunction, ECIS
Abbreviations: EC, endothelial cell(s); SDF-1, stromal cell-derived factor-1; PECAM-1, platelet/endothelial cell adhesion
molecule-1; ITAC, interferon-inducible T Cell Alpha Chemoattractant; ECIS, Electrical Cell Substrate Impedance Sensing; LEC,
lymphatic endothelial cells; BEC, blood vascular endothelial cells

The homeostatic function of endothelial cells (EC) is critical for a number of physiological processes including vascular
integrity, immunity, and wound healing. Indeed, vascular abnormalities resulting from EC dysfunction contribute to the
development and spread of malignancies. The alternative SDF-1/CXCL12 receptor CXCR7 is frequently and specifically
highly expressed in tumor-associated vessels. In this study, we investigate whether CXCR7 contributes to vascular dysfunction by specifically examining the effect of CXCR7 expression on EC barrier function and motility. We demonstrate
that CXCR7 expression in EC results in redistribution of CD31/PECAM-1 and loss of contact inhibition. Moreover, CXCR7+
EC are deficient in barrier formation. We show that CXCR7-mediated motility has no influence on angiogenesis but contributes to another motile process, the invasion of CXCR7+ EC into ligand-rich niches. These results identify CXCR7 as a
novel manipulator of EC barrier function via alteration of PECAM-1 homophilic junctions. As such, aberrant expression of
CXCR7 in the vasculature has the potential to disrupt vascular homeostasis and could contribute to vascular dysfunction
in cancer systems.

Introduction
Endothelial cells (EC) line the vasculature of both the blood
and lymphatic circulatory systems. As the “gate-keepers” of the
vasculature, EC play critical roles in a variety of physiological processes including development, tissue and vascular fluid
homeostasis, immune surveillance, and wound healing. In normal adult vasculature there is very little growth or turnover of
EC because stable cell–cell and cell–substrate contacts regulate
long-term survival and homeostatic functions. Moreover, these
contacts, as well as their regulation and signaling outcomes,
dictate EC barrier function and the maintenance of vascular
homeostasis. The formation and maintenance of the EC barrier
as well as its disruption in inflammation is a subject of continuing investigation.1 In contrast to normal vessels, the vasculature found in solid tumors is structurally and functionally
abnormal. This phenomenon, termed tumor vascular dysfunction, is linked to abnormalities in EC barrier function and ultimately results in tissues with poor oxygenation, low pH, and
high interstitial pressure, thus producing a microenvironment

that reduces immune surveillance and drives tumor growth and
metastasis.2,3
The chemokine SDF-1/CXCL12 and its canonical receptor
CXCR4 are among the most highly studied chemokine/receptor
pairs in cancer biology.4,5 CXCR4/SDF-1 interactions are known
to drive cellular motility and metastasis in a variety of malignancies. Interestingly, a second receptor for CXCL12 was recently
discovered and designated CXCR7.6 The existence of a second
receptor for SDF-1/CXCL12 necessitates a re-evaluation of the
effects of SDF-1 in cancer models. Moreover, CXCR7 binding to
its alternate ligand ITAC/CXCL11 also has the potential to influence tumor progression.7 Studies of CXCR7 expression in tumor
tissues reveal only sporadic expression on malignant cells in a
variety of cancers.8-13 However, several studies have reported that
CXCR7 is specifically expressed in EC of tumor vasculature9,14,15
and CXCR7 may be a specific marker for tumor vessels.10 Our
laboratory has observed that CXCR7 is uniformly overexpressed
in Kaposi sarcoma (KS) tumor cells, which are of EC origin16 as
well as in normal EC following infection with Kaposi sarcoma
herpesvirus (KSHV) in vitro.17 Despite the compelling evidence
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that CXCR7 is specifically expressed on tumor-associated EC,
the functional consequences of CXCR7 expression are illdefined. We have previously reported that CXCR7 expression
in EC results in aberrant post-confluent proliferation of EC cultures via proteasomal degradation of the Retinoblastoma protein (pRb).18 Moreover, in that previous study, we obtained data
indicating that CXCR7+ EC are not contact inhibited and form
abnormal monolayers.
Much of the current literature addressing the CXCL12 receptors characterizes CXCR7 as a decoy receptor. Decoy receptors
typically lack intrinsic signaling activity and exert their physiological effects by sequestering chemokine ligands, thereby altering chemotactic gradients at alternate receptors. As such, several
studies have shown that binding of CXCR7 to its ligands produces
no G-protein-mediated signaling19 but that CXCR7-expressing
cells modulate the free concentration of SDF-1/CXCL12 and can
thereby alter responses from CXCR4 and CXCR3.9,20,21 Several

Results
CXCR7 expression results in removal of CD31/PECAM-1
from cell–cell junctions
For the studies described herein, we chose to use primary or
HPV E6/E7-immortalized human lymphatic EC (pLEC and
iLEC, respectively) due to the fact that they (1) display robust
growth and junctional stability in the absence of shear stress and
(2) have uniformly low endogenous levels of CXCR7 under normal culture conditions (data not shown). However, key findings
of this study were verified in blood vascular-lineage EC (BEC) to
verify that phenotypes were not lineage-specific. CXCR7 expression was achieved via transduction of LEC with our previously
described tet-inducible adenovirus vector expressing a full-length
version of human CXCR7 containing an N-terminal HA-tag.18
CXCR7 expression from this vector is controlled by co-infection
with a second adenovirus vector expressing the tet-transactivator
(herein referred to as Trans). In all experiments, infection with
Trans only is used to control for non-specific effects of adenovirus transduction.
Platelet endothelial cell adhesion molecule-1 PECAM-1/CD31
is highly enriched at EC cell–cell junctions and, although it is not
required for junction formation,23 PECAM-1 has been shown to
play important roles in EC barrier function,24 the response of EC
to inflammatory stimuli25,26 and the transendothelial migration
of lymphocytes.27 Therefore, we wanted to determine whether
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Figure 1. CXCR7 expression results in removal of CD31/PECAM-1 from
cell-cell junctions. pLEC were infected with Trans or Trans+CXCR7. (A) At
20 h post-infection cultures were fixed and stained by IFA for PECAM-1
(green), CXCR7 (red), and DAPI. The white star marks the nucleus of an
internal control CXCR7 negative cell in contrast to CXCR7+ cell denoted
by white triangle. Scale bar is 30 µm. (B) Identical cultures were lysed
and analyzed by western blot for GAPDH and CD31/PECAM. Data are
representative of three replicate experiments. Membranes were then
reprobed for HA to verify adenovirus transduction efficiency. The star
(*) denotes a non-specific band commonly detected by HA antibody in
pLEC lysates. As with many proteins containing multiple transmembrane
domains, HA-CXCR7 in boiled lysates appears as a smear due to aggregation of the hydrophobic domains.

recent studies have also reported a non-scavenging function of
CXCR7 in specific cell types.22 Similarly, our previous experiments in EC showed that (1) endogenously produced CXCR7
ligands were required for CXCR7-mediated degradation of pRb
and (2) CXCR3 and CXCR4 protein levels were low or absent
(respectively) in this context and were not affected by CXCR7
expression.18 Therefore, we concluded that our gain-of-function
phenotypes were a result of CXCR7 signaling and that CXCR7
can function as a bona fide chemokine receptor in EC, making
its EC-specific expression in solid tumors of particular interest
and significance.
In the current study, we extend our previous findings by specifically examining the effect of CXCR7 on EC barrier function
and motility. We demonstrate that CXCR7 expression alone is
sufficient to remove CD31/PECAM-1 from cell–cell junctions
in confluent EC cultures. We present evidence that CD31 relocalization is associated with alterations in EC morphology and
present further evidence that CXCR7+ EC have lost contact
inhibition. Using Electrical Cell-Substrate Impedance Sensing
(ECIS) to allow real-time electrical monitoring of barrier function, we demonstrate that CXCR7+ EC are defective in barrier
formation and display characteristics of increased micromotion.
CXCR7-mediated motility does not contribute to tubule formation in vitro but affects another motile process, invasion of
CXCR7+ cells into ligand-rich niches. Taken together, these data
demonstrate that CXCR7 expression has profound effects on EC
homeostatic functions and suggest that CXCR7 may contribute
to vascular dysfunction in cancer.

Figure 2. CXCR7+ EC display altered morphology and lack contact inhibition. pLEC were infected with Trans+CXCR7. At 20 h post-infection cultures were fixed and stained by IFA for PECAM-1 (green), CXCR7 (red),
and DAPI. (A) A field of interest was selected and a z-stack series of 40
images with 0.1 µM step size was photographed at 100X magnification.
The image was subjected to deconvolution analysis. Nuclei of CXCR7
negative cells are marked with white stars, the nucleus of the CXCR7+
cell is marked with a white triangle. Scale bar is 20 µm. A region of interest (white box) containing both CXCR7 staining and junctional CD31
staining was extracted and (B) subjected to 3-dimensional analysis.
White dashed lines denote the region in the x-y plane containing junctional CD31 staining.

(indicated by white dashed lines) resides predominantly in the
bottom half of the z-stack whereas the CXCR7 staining resides
in the top half of the z-stack together with diffuse, non-junctional PECAM-1 staining (Fig. 2B, bottom). These data indicate
that the loss of junctional PECAM-1 in CXCR7+ EC is associated with the ability to grow on top of an ordered monolayer,
a characteristic of EC that have lost contact inhibition. We did
not observe a redistribution of PECAM-1 staining in CXCR7+
EC at 60X magnification (Fig. 1A), probably due to the relative
intensity of the tightly clustered junctional PECAM-1 staining at
this magnification. However, at 100x magnification, disordered
PECAM-1 staining is visible in both the x-y plane (Fig. 2B, top)
and is specifically localized to the top half of the z-stack, coincident with CXCR7 staining (Fig. 2B, bottom). Taken together
with our western blot data demonstrating that CXCR7 expression
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CXCR7 expression affected PECAM-1 homophilic junctions
in confluent EC monolayers. For these experiments, we allowed
pLEC cultures to grow 2 d past confluence to facilitate formation of a monolayer with mature junctions. We then infected
monolayers with Trans only or Trans+CXCR7 adenovirus. At
20 h post-infection, cultures were fixed and stained for CXCR7
and PECAM-1 using indirect immunofluorescence (IFA). While
transduction with the Trans adenovirus alone did not disrupt
PECAM-1 junctions compared with uninfected pLEC (data not
shown), we observed decreased junctional PECAM-1 staining
in CXCR7-expressing EC to a degree that was inversely correlated with the intensity of CXCR7 staining on a per cell basis
(Fig. 1A, white triangle). Moreover, adjacent CXCR7-negative
cells in the same cultures (Fig. 1A, white star) retained peripheral PECAM-1 staining suggesting that this effect is cell-autonomous and not due to the release of paracrine factors. Given that
intercellular homophilic PECAM-1 interaction is important for
stable junctional retention of PECAM-1,28,29 we believe that the
peripherally expressed PECAM-1 in CXCR7-negative cells lying
adjacent to CXCR7-positive cells that lack peripheral PECAM-1
constitutes PECAM-1 molecules that are continuously recycling
between the junctional space and the lateral border recycling
compartment (LBRC).30 This PECAM-1 expression pattern was
reproducible in multiple fields in five independent experiments
and similar results were obtained in primary blood vascular EC
(pBEC) cultures, indicating that the phenotype is not restricted
to the lymphatic EC lineage (data not shown). Next, we examined total PECAM-1 levels via western blot in identical pLEC
cultures transduced with either Trans or Trans+CXCR7. These
experiments revealed no reduction in total PECAM-1 expression in CXCR7-expressing EC relative to the Trans control
(Fig. 1B), consistent with PECAM-1 relocalization as opposed
to degradation.
CXCR7+ EC display altered morphology and lack contact
inhibition
Careful examination of CXCR7-expressing pLEC cultures by
IFA revealed a large number of CXCR7+ cells with elongated
morphology that were apparently growing on top of CXCR7negative cells. Multi-layered growth is remarkable in EC cultures, which are highly contact inhibited. In order to verify these
observations, we performed 3-dimensional microscopic analysis
of high magnification z-stacks on the CXCR7+ cells that were
growing on top of the monolayer. Figure 2 shows a representative
analysis of one such field acquired via a 40-image z-stack at 0.1
µM step size and 100X magnification and subjected to deconvolution analysis. In this image, a single CXCR7+ cell (Fig. 2A,
white triangle) with an elongated projection staining for CXCR7
but lacking any peripheral PECAM-1 staining apparently lies on
top of four CXCR7-negative EC (Fig. 2A, white stars), which
display normal junctional PECAM-1. In order to verify that the
CXCR7+ cell was indeed in a different z-plane than the cells
with junctional PECAM-1 staining, we chose a region of interest
within the field where both CXCR7 and PECAM staining were
evident (Fig. 2A, white box) and performed 3-dimensional rotational analysis (Fig. 2B). Indeed, rotation of the image around
the x-axis reveals that the intense junctional PECAM-1 staining

does not reduce total PECAM-1 expression (Fig. 1B), the data
indicate that CXCR7 expression is mediating redistribution of
PECAM-1 to extra-junctional sites.
CXCR7+ EC are defective in barrier formation
We next wanted to determine whether loss of junctional
PECAM-1 in CXCR7+ EC resulted in defects in the ability of these
EC to form a tight barrier. For these experiments, we used a technique called Electrical Cell-Substrate Impedance Sensing (ECIS)
in which cells are plated into multi-well arrays that contain electrodes on the growth surface. The growth media and the electrodes
comprise an electrical circuit. As the cells spread and grow over
the electrodes they form an insulating layer, thereby increasing the
impedance of the system, which is measured in real-time without

damaging the cells.31,32 In the case of a confluent layer of EC, the
impedance value is a real-time, quantitative measure of the barrier
integrity, with the magnitude and stability of impedance values
being indicative of junctional integrity.33 We infected pLEC with
Trans or Trans+CXCR7. At 20 h post-infection, cells were trypsinized and 3 ´ 105 cells per well were replated into duplicate wells on
ECIS arrays and allowed to adhere and spread. Because cell adherence and barrier formation requires coordinated cell movement,
we also included SDF-1/CXCL12 at 10 ng/ml in replicate wells to
determine whether CXCR7 ligands affect this process. At the cell
concentration used, we expect the formation of a confluent monolayer without the need for cells to proliferate on the ECIS array.
Impedance measurements were recorded every 8 s for a further 25
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Figure 3. CXCR7+ EC are defective in barrier formation. pLEC were infected with Trans or Trans+CXCR7. (A) At 20 h post-infection cells were trypsinized
and replated onto ECIS arrays with or without SDF-1/CXCL12 at 10 ng/ml and allowed to attach for 25 h. Impedance readings at 4000 Hz were taken every
8 s throughout the timecourse. Individual wells were normalized to impedance at t = 0 and duplicate wells were averaged to create the impedance
curves. Data are representative of duplicate wells from three independent experiments. (B) At the time of ECIS seeding, a subset of cells was reserved
for analysis of CXCR7 and CXCR4 expression by flow cytometry. Necrotic cells were excluded from the analysis via propidium iodide staining and scatter
characteristics. (C) Duplicate multi-well plates seeded identically to ECIS arrays were fixed at 25 h post-seeding and stained for CXCR7 (red), PECAM-1
(green), and DAPI and analyzed by deconvolution microscopy.

©2012 Landes Bioscience. Do not distribute.
Figure 4. CXCR7+ EC display increased micromotion by ECIS. (A) Extracted impedance readings from ECIS traces scaled to 2 h by 100 ohms. Curves
shown are impedance traces of pLEC infected with Trans or Trans+CXCR7 and treated with media only (Unstimulated, top 3 panels) or 10 ng/ml SDF-1/
CXCL12 (bottom three panels). Symbols indicated for each experiment correspond to the data points shown in (C). (B) Overlayed time differential (left)
and binned histograms of time differential data (right) for Trans (black, overlayed) and Trans+CXCR7 (blue, underlayed) corresponding to the same panels in (A). (C) Quantitation of the standard deviation of impedance fluctuations in Trans or Trans+CXCR7 cultures with or without 10 ng/ml SDF-1/CXCL12.
Analysis includes duplicate wells from three independent experiments (black data points) and the average for each condition (gray bar).
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generate the plotted impedance curves. As expected, control
Trans cells attached to the substrate within 2 h post-seeding,
as indicated by an initial plateau of impedance values during
this time period. Impedance values increased again between 2
and 5 h post-seeding as cells spread and cell-cell junctions were
formed, after which impedance values reached a second plateau
and remained stable throughout the rest of the timecourse,
coincident with junction maturation (Fig. 3A, black curve).
Treatment of Trans cells with SDF-1/CXCL12 did not significantly affect either the timecourse or final impedance values of
barrier formation and maturation (Fig. 3A, blue curve). The
timecourse of initial attachment for CXCR7+ EC was comparable to Trans (Fig. 3A, red curve). However, in contrast to
Trans controls, the kinetics of junction formation and maturation was significantly slowed in CXCR7+ EC over the timecourse with CXCR7+ EC taking 5–7 h longer to reach the
same impedance levels achieved in Trans controls. This delay
in barrier formation occurred regardless of ligand stimulation
(Fig. 3A, red and green curves). Despite the delay in junction
formation and maturation untreated CXCR7+ cultures stabilized at the same impedance level as Trans controls (Fig. 3A,
red curve). In contrast, the SDF-1/CXCL12-treated CXCR7+
cultures displayed increased impedance compared with Trans
or untreated CXCR7+ conditions (Fig. 3A, green curve).
Similar trends were observed in replicate experiments. A subset of cells was reserved prior to seeding in ECIS arrays and
stained by flow cytometry for surface expression of CXCR7
and the alternate SDF-1/CXCL12 receptor CXCR4 (Fig. 3B).
As expected, CXCR7 transduction was very efficient and no
CXCR4 was present at the cell surface in either condition.
Therefore, the observed phenotypes are a product of CXCR7
gain-of-function and are not influenced by CXCR4. IFA analysis of duplicate cultures were fixed and stained for PECAM-1
and CXCR7 at 25 h post-seeding revealing abnormal monolayers in the CXCR7+ conditions (Fig. 3C), consistent with
our previously published data.18 Moreover, our previous report
demonstrated that CXCR7+ EC are hyperproliferative in
response to CXCR7 ligands.18 Taken together with our data
from this study indicating that CXCR7+ EC are able to grow
on top of a confluent monolayer (Fig. 2), we believe that the
increased impedance observed in the SDF-1/CXCL12-treated
cultures (Fig. 3A, green curve) is representative of aberrant
proliferation and the formation of multi-layered structures
rather than the formation of a functional quiescent barrier.
Figure 5. CXCR7 expression does not affect angiogenesis. pLEC were infected
Higher doses of SDF-1/CXCL12 did not alter the observed
with Trans or Trans+CXCR7. At 20 h post-infection cells were trypsinized and
replated onto matrigel in complete medium or serum-free medium with or
phenotype (data not shown). Similar experiments in which
without SDF-1 at 50 ng/ml. Tubule formation was analyzed at 24 h post-platcells were stimulated with ITAC/CXCL11 revealed non-speing by (A) light microscopy and (B) quantitation of branch points in 3–5 wells
cific effects of this chemokine on barrier formation in Trans
per condition from four independent experiments. P > 0.8 for Trans vs. CXCR7
controls, possibly due to low levels of CXCR3 expression18
in all conditions. P > 0.2 for SFM vs. SDF-1 for both Trans and CXCR7.
(data not shown). These results demonstrate that CXCR7
expression in EC compromises their ability to form cell-cell
h. In order to get an overall view of barrier formation in these cul- junctions and establish barrier function, a phenotype that could
tures, we used ECIS arrays that collect and average the impedance have significant implications for vascular function.
recordings of 40 electrodes distributed across the culture growth
CXCR7+ EC display increased micromotion by ECIS
surface. Data from at least two independent wells representing 80
In our ECIS experiments, the impedance measurement curves
individual impedance readings at each timepoint were averaged to were highly unstable in CXCR7+ conditions compared with
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Trans controls when short time intervals were inspected at
narrow impedance ranges. In order to better illustrate these
small-scale fluctuations, we extracted 100 ohm impedance
windows for 2-h time periods following barrier formation
for a replicate well from each of three independent experiments (designated Exp 1, 2, and 3) wherein each curve
represents the average of 40 individual electrode measurements every 8 s (Fig. 4A). At this scale, we can clearly
see increased small-scale variability of impedance measurements exclusively in the CXCR7+ conditions. These
impedance fluctuations were consistent throughout the
timecourse following the period of attachment and spreading (data not shown). In order to quantitatively analyze
this phenotype and determine its ligand-dependence, we
developed an algorithm in which the time derivative of the
impedance measurements was calculated for each condition. The timepoints following attachment and spreading
were used for the analysis in order to quantify fluctuations
irrespective of the total impedance values (Fig. 4B, left). To
allow for relative comparison, the time derivative data for
Trans (black) was overlayed onto the CXCR7 data (blue).
From this data, a binned distribution of the magnitudes of
short-timescale impedance variability for each sample was
created (Fig. 4B, right) and the standard deviation of this
distribution was used as a measure of the overall impedance
Figure 6. CXCR7 expression enhances EC invasion toward CXCR7 ligands. iLEC
fluctuation for each condition (Fig. 4C). We can clearly see
were infected with Trans or Trans+CXCR7. At 20 h post-infection cells were
in the overlayed time derivative data that in all conditions
labeled with Calcein-AM dye, trypsinized, and transferred to matrigel-coated
CXCR7 expression increases the magnitude of impedance
Fluoroblok™ invasion plates with ITAC/CXCL11 at 50 ng/ml, SDF-1/CXCL12 at
50 ng/ml, or no ligand in the bottom chamber. Invasion was measured via fluvariability. In one experiment, there was a highly signifiorescence accumulation in the bottom chamber at the indicated timepoints.
cant increase in impedance fluctuations in CXCR7+ EC
Individual wells were normalized to fluorescence intensity at t = 0 and RFU
treated with SDF-1/CXCL12. This effect was reproducible
increases were averaged for each condition. n = 16 wells per condition and
in additional experimental replicates but not to the same
data are representative of three independent experiments. **P < 0.001 for both
magnitude; this variability is likely due to varying levels of
CXCR7+SDF-1 and CXCR7+ITAC compared with unstimulated Trans control. A
subset of cells was stained prior to seeding for HA-CXCR7 by flow cytometry to
endogenous ligand in the individual wells. This analysis
control for adenovirus transduction efficiency (histogram, inset).
reveals that (1) the visual quality of the curves corresponds
to a mathematically demonstrable increase in short-timescale variability and (2) that there is evidence for some degree of CXCL12 into the matrigel matrix. Tubule formation was pholigand-dependence with this phenotype. Such small-scale imped- tographed at 24 h post-seeding (Fig. 5A) and branch points per
ance fluctuations are characteristic of cellular micromotion31 and field were quantified for three to five biological replicates in four
have been used to distinguish malignant cells from non-malignant independent experiments (Fig. 5B). Appreciable tubule formacells34 and can also be correlated with the invasive and metastatic tion was seen in all conditions, and although there was a slight
potential of cancer cell lines in vitro.35 We thus conclude that this trend toward higher numbers of branch points in the SDF-1/
aspect of our ECIS data are similarly indicative of increased motil- CXCL12-treated conditions, there was no statistically significant
ity in CXCR7+ EC.
effect of either CXCR7 expression or SDF-1/CXCL12 treatment
CXCR7 expression does not affect angiogenesis
on in vitro tubule formation. This data suggested that CXCR7
In order to confirm whether the increased variability of signaling does not affect the coordinated EC motility necessary
ECIS measurements correlates with increased motility in for tubule formation. We obtained similar results in duplicate
CXCR7+ EC, we next performed specific functional assays for conditions performed with different doses of SDF-1/CXCL12
EC motility. First, we tested whether CXCR7 expression and/ (data not shown), demonstrating that the lack of an SDF-1/
or SDF-1/CXCL12 treatment affected the ability of EC to form CXCL12 response is not a result of the ligand dosage.
tubules in an in vitro angiogenesis assay. Accordingly, Trans or
CXCR7 expression enhances EC invasion toward CXCR7
Trans+CXCR7-infected pLEC were replated on to a matrigel ligands
matrix in medium lacking serum or growth factors but suppleWe next utilized an in vitro invasion assay to determine whether
mented with or without 50 ng/ml SDF-1/CXCL12. We used CXCR7 enhances single-cell chemotactic motility in EC. For this
higher concentrations of SDF-1/CXCL12 in these assays in assay, Fluoroblok™ invasion chambers were coated with Matrigel
order to allow for diffusion of effective concentrations of SDF-1/ (BD) and allowed to solidify overnight at 37 °C. Fluoroblok™

Discussion
In the current study, we sought to determine whether CXCR7
expression in the vasculature could contribute to tumor vascular dysfunction by affecting EC barrier function. We demonstrate that CXCR7 expression in EC has the capacity to remove
PECAM-1 from cell–cell junctions resulting in a loss of contact
inhibition and defects in endothelial barrier formation. The lack
of contact inhibition and aberrant barrier function seen in this
study is consistent with our previous results demonstrating that
CXCR7+ EC are hyperproliferative and form abnormal monolayers in culture.18 In the current study, we further demonstrate
that CXCR7+ EC are hypermotile and that this motility is sufficient to direct invasion of CXCR7+ EC into niches containing CXCR7 ligands. Taken together, these results provide strong
evidence that aberrant CXCR7 expression results in significant
disruption of EC homeostatic functions. As such, we believe this
study identifies CXCR7 as a potential mediator of vascular dysfunction and a target for therapeutic intervention.
A variety of studies in PECAM-1-knockout mice have
revealed the critical contribution of PECAM-1 expression to
vascular integrity, particularly under conditions of physiological
stress.25,26 PECAM-1 signaling via tyrosine phosphorylation of

its Immunoreceptor tyrosine inhibitory motifs (ITIMs) has been
linked to a variety of EC functions, including interactions with
immune cells and cellular motility.36,37 Interestingly, a recent study
found that the localization of PECAM-1 to cell–cell junctions and
homophilic PECAM-1 interactions mediated EC barrier formation and plasticity even in the absence of PECAM-1 signaling.38
Our current study establishes CXCR7 as a novel manipulator of
EC barrier function via manipulation of PECAM-1 localization.
Recently, PECAM-1 signaling in EC was shown to affect the proliferation of advanced metastatic tumor cells via the release of paracrine factors.39 Intriguingly, this study showed that administration
of a PECAM-1-targeting antibody could slow the formation and
growth of advanced metastases in mice, identifying PECAM-1 as
a potential target for the treatment of advanced cases of cancer.
However, the specific effect of this therapeutic PECAM-1 antibody on PECAM-1 localization, expression, and signaling remains
unclear. It would be interesting to determine whether, in advanced
metastatic lesions, CXCR7 expression in vascular EC results in a
redistribution of PECAM-1 from EC junctions to other cell compartments such as the LBRC, where it then participates in the
release of paracrine factors or other activities that affect tumor cell
growth. Moreover, future studies of the effect of CXCR7 expression on other EC junction and adhesion molecules are warranted.
The signaling mechanisms underlying CXCR7-mediated redistribution of PECAM-1 will also be a critical subject for future
research. Given that CXCR7 does not exhibit classic G-proteinmediated signaling in most cellular contexts, the downstream
signaling molecules activated by ligand-dependent CXCR7 signaling remain obscure. Our results presented herein justify studies
into effects of CXCR7 on signaling mechanisms in EC known to
modulate PECAM-1 localization and enhance cell motility such as
mitogen-activated protein (MAP) kinase signaling.40
Tumor vascular dysfunction exacerbates the development
and spread of cancer by selecting for tumor cells that can survive and proliferate under adverse conditions, thereby enhancing malignancy and driving the development of metastases. As
such, treatments that normalize the tumor vasculature have the
potential to simultaneously slow the emergence of metastatic
disease and improve delivery of chemotherapeutic agents into
the primary tumor.2 Despite promising results from animal
models, the response of human cancers to vascular normalization therapy via VEGF-targeted agents has been modest and
has achieved only moderate short-term efficacy in combination
therapy. Moreover, the current VEGF-targeting agents have
significant drawbacks in several cancers including neoplasms
of the central nervous system and pediatric solid tumors.3,41,42
These studies have validated vascular normalization as a new
paradigm for chemotherapy, yet underscore the need for new
therapies that more specifically target the tumor vasculature.
In this study, we demonstrate that CXCR7 expression in EC
results in abnormalities in barrier function and enhanced invasion. Taken together with the compelling observation that
tumor-associated endothelium is almost uniformly CXCR7+
regardless of the cancer type,10 we believe that CXCR7 represents a potential therapeutic target for tumor vascular normalization therapy.
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plates contain membranes that are impermeable to fluorescent
light, allowing sequential reads of fluorescence in the bottom
chamber without disassembling the invasion plate. iLEC were
infected with Trans or Trans+CXCR7. At 20 h post-infection,
cells were labeled with the membrane-permeable dye Calcein-AM,
trypsinized and replated at 2 ´ 104 cells/well into the top chambers
of the invasion plate. Media only, 50 ng/ml SDF-1/CXCL12 or
50 ng/ml ITAC/CXCL11 was added to the bottom chambers to
provide the chemotactic stimulus. As in the Matrigel angiogenesis experiments, these higher concentrations of chemokine (50
ng/ml) were used to allow for diffusion of the chemotactic gradient through the Matrigel barrier to the target cells. We assayed
invasion by reading bottom chamber fluorescence at 1, 2, 4, 24,
30, and 48 h post-seeding. The background fluorescence was subtracted for each well and invasion was calculated based on the average RFU increase over baseline fluorescence values. We observed
that control Trans EC invade at the same rate regardless of the
presence or absence of a chemotactic stimulus. CXCR7+ EC in
the absence of ligand invaded slightly faster than Trans controls
between 4 and 24 h post-seeding. This difference was reproducible in multiple experiments, but was not statistically significant
compared with unstimulated Trans controls. However, addition of
either SDF-1/CXCL12 or ITAC/CXCL11 as a chemotactic stimulus significantly increased the invasion of CXCR7+ EC compared
with untreated Trans controls (Fig. 6). Increased invasion in the
ligand-treated conditions was statistically significant compared
with unstimulated Trans controls as early as 4 h post-seeding.
These data demonstrate that CXCR7+ EC are indeed hypermotile, as suggested by our ECIS data (Fig. 4), and that this motility
is sufficient to mediate ligand-dependent but not ligand-specific
invasion of CXCR7+ EC through a matrigel barrier.

Materials and Methods
Cell lines and reagents
Primary adult lymphatic endothelial cells (pLEC) and primary
adult blood vascular endothelial cells (pBEC) were commercially
obtained (Lonza CC-2810 and CC-2811, respectively) and iLEC
were immortalized by transduction with the recombinant retrovirus LXSN16 E6E7 as described previously.47 EC lines were maintained in EGM-2 medium (Lonza #CC-3024) containing bullet
kit growth supplements (Lonza #CC-3124), 10% fetal bovine
serum (FBS, Hyclone SH30396.03), and Penicillin/Streptomycin/
L-Glutamine (PSG, Hyclone SV30082.01). Primary EC cultures
were used between passage 4 and 10; immortalized EC were used
between passage 7 and 14. MouseIgG1-anti-CXCR7 antibody
(11G8) was kindly provided by Chemocentryx. MouseIgG2aanti-CD31/PECAM-1 antibody for indirect immunofluorescence
(IFA) and western blot was from Thermo/Fisher (MA3100).
AlexaFlour647-conjugated-rabbit-anti-HA antibody (sc-805) and
HRP-conjugated anti-mouse (sc-2306) were from Santa Cruz
Biotechnology. GAPDH antibody was from Abcam (ab8245).
Anti-mouseIgG2a-AlexaFluor488 (A21131), anti-mouseIgG1AlexaFluor594 (A21125), anti-rabbit-AlexaFluor488 (A110088),
and Calcein-AM (C3100MP) were from Invitrogen. HA-HRP
direct conjugate was from Roche (12013819011). Recombinant
human SDF-1/CXCL12 (350-NS-050) and recombinant human
ITAC/CXCL11 (672-IT-025) were from R&D Systems. Growth
Factor Reduced High Concentration Matrigel was from BD
Biosystems (354263). Propidium Iodide was from Sigma (P4170).
CXCR7 adenovirus vectors
CXCR7-expressing vectors with an N-terminal HA tag were
described previously.18 This vector contains the tet-responsive
enhancer within a minimal CMV promoter followed by the
SV40 late poly(A) cassette, adenovirus E1A, and a single loxP site

to increase recombination frequency. Recombinant adenoviruses
were produced by co-transfection of 293 cells expressing the Cre
recombinase with adenovirus DNA (Ad5-ψ5) that contains an
E1A/E3-deleted adenovirus genome and pAdtet7-HA-CXCR7.
Recombinant adenoviruses were expanded on 293-Cre cells,
purified by sucrose gradient ultracentrifugation, and titered on
293 cells by limiting dilution. Expression was driven by co-infection with Ad-Trans expressing the Tet-off transactivator.
Infection of EC with adenovirus vectors
Adenovirus infections were performed on confluent EC cultures in endothelial SFM medium (endoSFM, Gibco 11111) supplemented with 1% FBS, PSG, and 37.5 µg/ml endothelial cell
growth supplement (ECGS, BD Biosystems 356006).
Indirect immunofluorescence (IFA) for EC junctions
EC were plated on collagen-coated coverslips (BD Biosystems
354089) and infected with either the adenovirus expressing Trans
alone at MOI 100, or Trans at MOI 100 and CXCR7 at MOI
100. At 20 h post-infection, cells were washed once with PBS+ and
fixed in PBS+ containing 2% paraformaldehyde (PFA) and 1%
TritonX-100 for 15 min at room temperature (RT). Coverslips were
then post-fixed for a further 5 min at RT in PBS+ containing 2%
PFA only. Coverslips were blocked in PBS+ with 1% TritonX-100
and 2% normal goat serum (NGS) for 15 min at RT. All further incubations were performed in PBS+ with 1% TritonX-100
and 0.2% NGS. Coverslips were incubated with MouseIgG2aanti-CD31/PECAM and MouseIgG1-anti-CXCR7 primary antibodies at 1:100 dilution for 30 min at RT in a humidity chamber.
Coverslips were washed twice for 10 min and incubated with antimouseIgG2a-AlexaFluor488 and anti-mouseIgG1-AlexaFluor594
secondary antibodies and DAPI at 1:1000 dilution for 30 min at
RT in a humidity chamber. Following secondary antibody incubation, coverslips were washed three times for 10 min and mounted
on glass slides using Fluoromount G (Southern Biotech).
Indirect immunofluorescence image acquisition and analysis
Image acquisition and analysis was performed on a Deltavision
Real-Time Deconvolution Microscope using Softworx analysis
software (Applied Precision). Unless otherwise indicated, z-stacks
with a 0.2 µm z-step size were taken at 60X magnification. Stacks
were subjected to deconvolution analysis and 2–3 section projections were made superimposing representative z-planes to generate the final image. For 3-dimensional analysis, 40-section
z-stacks with a 0.1 µm z-step were taken at 100X magnification,
a region of interest was selected and the entire 40-image z-stack
was processed by rotational transformation around the x-axis to
generate the x-z image.
Western blot analysis
Cells were lysed in 200 µl modified radioimmunoprecipitation (RIPA) buffer (10 mM Tris pH 7.4, 150 mM NaCl, 1 mM
EDTA, 1%Triton-X-100, 1% Sodium Deoxycholate, 0.1% SDS)
containing protease inhibitors (Roche 11836145001) for 10 min
on ice. Lysates were freeze-thawed once at -20 °C and protein was
quantified by BCA protein assay (Pierce, 23225). 0.5 µg of total
lysate was boiled for 5 min in 1X LDS protein sample buffer containing reducing agent (Invitrogen, NP0009), loaded on NuPAGE
4–12% Bis-Tris gradient protein gels (Invitrogen, NP0335), and
run in 1X NuPAGE MOPS buffer (Invitrogen, NP0001). Protein
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When it was still the orphan GPCR RDC-1, we found that
CXCR7 is a critical mediator of EC transformation by the oncogenic γ-herpesvirus KSHV.17 The tumor cells, known as spindle
cells, of Kaposi sarcoma (KS) lesions are uniformly infected with
KSHV and are of EC-origin.43-45 As such, our data demonstrating that CXCR7 expression alters EC homeostatic functions has
significant implications for the pathogenesis of KS. Indeed, the
enlongated morphology of CXCR7+ EC we observed growing on
top of CXCR7 negative EC (Fig. 4A) is reminiscent of the spindle
cell phenotype acquired by KSHV-infected EC in vitro as well as
KS tumor cell morphology in vivo. The molecular factors that drive
the preferential incidence and recurrence of KS lesions in the skin
and at sites of injury and inflammation have never been adequately
cataloged. Interestingly, KSHV-infected cells have been shown to
undergo transendothelial migration in response to chemotactic
gradients of SDF-1/CXCL12.46 Taken together with the results of
our current study showing that CXCR7+ EC invade in response
to an SDF-1/CXCL12 gradient, these data support the hypothesis
that the induction of CXCR7 by KSHV is a critical factor for the
dissemination of KS. As such, we believe that the therapeutic value
of CXCR7-targeted therapy for KS deserves further study.

hundred µl of liquid matrigel was added to a chilled 24-well tissue culture plate and allowed to solidify for 30 min at 37 °C.
pLEC were infected with either the adenovirus expressing Trans
alone at MOI 100, or Trans at MOI 100 and CXCR7 at MOI
200. At 20 h post-infection, matrigel was overlayed with 200 µl
serum-free Medium 199 only, or medium supplemented with 50
ng/ml SDF-1/CXCL12. Cells were trypsinized, counted, and
overlayed onto matrigel and media at 5 ´ 104 cells per well in 200
µl of serum-free Medium 199. Each condition was performed in
three to five replicate wells per experiment. Tubule formation was
allowed to proceed for 20 h at 37 °C after which analysis was
performed by light microscopy at 5x magnification using a Zeiss
Axiovert 25 microscope and a Sony Cyber-shot digital camera.
Manual quantitation of branch points was performed on images
using ImageJ software.
Invasion assay
Matrigel was thawed on ice and diluted with cold serumfree Medium 199 to a final protein concentration of 5 mg/
ml. 25µl of liquid matrigel was added to each well of a 96-well
Fluoroblok™ invasion plate (BD Falcon, 351164) and allowed
to solidify overnight at 37 °C. iLEC were infected with either
the adenovirus expressing Trans alone at MOI 100, or Trans at
MOI 100 and CXCR7 at MOI 200. At 20 h post-infection, cells
were labeled with 2 µg/ml Calcein-AM in 1% endoSFM+ECGS
for 30 min at 37 °C. During labeling, SDF-1/CXCL12 at
50 ng/ml or ITAC/CXCL11 at 50 ng/ml was diluted in 1%
endoSFM+ECGS and added to bottom chambers at 200 µl per
well. Calcein-AM-labeled, cells were trypsinized, counted and
replated into the top chamber of the invasion plate at 2 ´ 10 4
cells per well in 50µl of 1% endoSFM+ECGS. Baseline fluorescence was read immediately on a Molecular Devices Flexstation
fluorescence plate reader set for 485 nm excitation and 525 nm
emission monochromators and a 515 nm cutoff filter. Invasion
plates were kept at 37 °C between timepoints and read at 1, 2, 4,
24, 30, and 48 h post-seeding. The baseline fluorescence reading for each well was subtracted from each timepoint and RFU
increases for biological replicates were averaged. P values for
were obtained via Student’s T-test with two tails and unequal
variance using Apple Numbers software. Values less than 0.01
were considered significant.
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was transferred to Immobilon-P blotting membrane (Millipore,
IPVH00010) and membranes were blocked by drying overnight
at RT. Membranes were rehydrated in 2% ECL advance blocking buffer (Amersham, CPK1075) with 0.2% Tween-20 (Block)
for 15 min. All subsequent incubations were performed in Block.
PECAM-1/CD31 primary antibody was at 1:1000 dilution and
GAPDH primary antibody was at 1:50 000 dilution for 1 h at
RT. Anti-mouse-HRP-conjugated secondary antibody was diluted
1:40 000 and incubated for 20 min at RT. Blots were developed
using ECL Advance (Amersham, RPN2135) chemiluminescent
reagent and autoradiography. Membranes were then air-dried overnight to inactivate bound HRP secondary antibodies. Membranes
were re-blocked as above and HRP-inactivation was verified by
incubation of membranes with ECL reagents and autoradiography.
Membranes were then blotted as above with a direct conjugate
anti-HA-HRP to verify the efficacy of adenovirus transduction.
Flow cytometry
Cells were dissociated with Cellstripper (Cellgro, 25-056-CI)
and resuspended in cold PBS+ containing 2% NGS and 0.1%
sodium azide (NaN3) (Surface Block) for 15 min on ice. Cells
were then incubated for 15 min on ice with mouse anti-CXCR7
(11G8) and CXCR4 (12G5) antibodies diluted 1:100 in cold PBS+
containing 0.2% NGS and 0.1% NaN3 (Surface Wash) followed
by 15 min on ice with anti-mouseIgG1-Alexa647 and anti-mouseIgG2a-Alexa488 secondary antibodies at 1:1000 dilution and 1 µM
propidium iodide (PI) in 100 µl Surface Wash. Analysis was on a
BD FACS Calibur flow cytometer. Live, non-necrotic cells were
gated based on scatter characteristics and negative PI staining.
ECIS barrier formation assay
pLEC were infected with either the adenovirus expressing
Trans alone at MOI 100, or Trans at MOI 100 and CXCR7
at MOI 200. 8W10E+ ECIS arrays (Applied Biophysics) were
cleaned with 200 µl per well of 10 mM l-cysteine for 15 min at
RT, rinsed twice with water, coated with 1% gelatin for 15 min at
RT, and equilibrated with complete EGM-2 medium for 30 min
at 37 °C. At 20 h post-infection, cells were trypsinized, counted,
and replated in complete EGM-2 at 3 ´ 105 cells/well in duplicate
on ECIS arrays with or without SDF-1/CXCL12 at 10 ng/ml.
Real-time impedance measurements at 4000 Hz were recorded
for each well every 8 s for 12 h on an ECIS Z unit (Applied
Biophysics). Impedance measurements for duplicate wells were
averaged and plotted using the ECIS software.
ECIS micromotion analysis
Following the statistical analysis presented in,48 cellular micromotion was quantified using a custom written MATLAB (The
MathWorks Inc.) program to numerically determine the time
derivative of impedance values yielding a temporal fluctuation
profile. The fluctuation profile was then binned into a histogram
and fit with a normal distribution. The full-width half-max of
the normal fit quantified the range of fluctuations irrespective
of the total impedance values. This procedure was performed for
each well individually over the portion of the timecourse that followed attachment and spreading.
Tubule formation assay
Matrigel was thawed on ice and diluted with cold serum-free
Medium 199 to a final protein concentration of 7 mg/ml. Three
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